Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 2025 February 25, 2026 Strong margin improvement to 16.3% in FY 2025 Positive growth outlook with continued margin expansion in 2026 New EUR 200 million share buyback
Reeves urged to cut bank tax as UK competitiveness lags February 25, 2026 Rachel Reeves is facing renewed calls to cut tax on the banking sector after new bombshell research laid bare the competitive disadvantage UK lenders are battling against. The Chancellor spared banks from a highly-anticipated fresh tax raid in the Autumn Budget but a new report – penned by the Association for Financial Markets (AFME) and [...]
Luxfer Delivers Strong Full-Year 2025 Profitability and Cash Generation February 24, 2026 Portfolio focus and favorable mix drive sustained profitability, enhanced adjusted earnings growth and strong cash flow generation Fourth Quarter 2025 Highlights* Net Sales declined 12.3% to $90.7 million from $103.4 million, while Adjusted Net Sales1 declined 5.5% Net Income of $0.1 million, compared to $3.3 million, and $0.12 per diluted share, with Adjusted Diluted EPS1 of $0.28 down 3.4% from $0.29 Adjusted EBITDA1 of $13.0 million, declined 5.8% Continued execution of previously announced operational excellence initiatives, including the Riverside and Powders Saxonburg centers of excellence, expected to drive improved efficiency and generate approximately $6 million of long-term annual savings Full Year 2025 Highlights* Net Sales declined 1.9% to $384.6 million from $391.9 million, while Adjusted Net Sales1 increased 2.5% Net Income of $13.1 million, or $0.48 per diluted share, compared to $18.3 million and $0.68 per diluted share, with Adjusted Diluted EPS1 of $1.11, up 12.1% from $0.99 Adjusted EBITDA1 of $51.9 million, up 4.2% Delivered strong free cash flow of $26.2 million, reducing net debt to $31.1 million Enhanced portfolio quality and strategic focus following completion of the Graphic Arts sale * Comparative information is relative to prior-year fourth quarter and full year; results exclude discontinued operations 1 Note: Adjusted results exclude Graphic Arts and 2024 legal fee recoveries
IGI Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results and Declares Ordinary Common Share Dividend February 24, 2026 International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today reported financial results for the fourth quarter and full year 2025. Highlights for the fourth quarter and full year 2025 include: (in millions of U.S. Dollars, except percentages and per share information) Quarter Ended December 31, Year Ended December 31, 2025 [...]
Retail investors become largest UK investment owners as wealth managers look elsewhere February 24, 2026 Retail investors solidified their place as the largest group of investment trust owners last year, as wealth managers and institutional investors decreased their holdings. As of 2025, retail investors hold a combined £50.5bn, equivalent to a 37 per cent stake, according to the latest state of the nation report from Warhorse Partners. This was up [...]
Lord Mandelson arrested: What led to police action? February 24, 2026 Peter Mandelson was arrested on Monday on suspicion of misconduct in public office, but how did we get here? The Metropolitan Police said in a statement on Monday evening that they had arrested a 72-year-old man in Camden. Mandelson was photographed being taken out of his house at 4:30 pm by detectives from the Met’s [...]
BioMed Realty and Babraham Research Campus Ltd Complete Lease-Up of Newest Building at Babraham Research Campus, with TRIMTECH Therapeutics and Tagomics February 24, 2026 BioMed Realty, the largest private operator of real estate for the life science and technology industries, today announced the completion of the lease-up of the newest laboratory building at Babraham Research Campus, following new leases with TRIMTECH Therapeutics and Tagomics Ltd. The fully occupied building represents another milestone in the joint venture between BioMed Realty [...]
Reform vow to create new ‘wealth fund’ using pension schemes February 23, 2026 Reform UK has pledged to create a new “British Sovereign Wealth Fund” using local government pension schemes as part of Richard Tice’s first policy package as the party’s spokesman for business, trade and energy. Reform has vowed to wrap various arms of government, including housing and energy, into one office that focuses on growth, job [...]
Rudding Park Selects Agilysys Hospitality Software Solutions to Modernise Guest Journeys and Streamline Operations Across Its Hotel Ecosystem February 23, 2026 The award-winning resort will deploy a unified Agilysys technology platform to replace disconnected systems, enabling seamless guest recognition and operational efficiency across its hotel, spa, golf, and dining amenities.
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights February 23, 2026 Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million Prothena expects the full year 2026 net cash used in operating and investing activities to be $50 to $55 million and expects to end the year with approximately $255 million in cash (midpoint). Financial guidance does not include the potential to earn up to $105 million in aggregate clinical milestone payments from strategic partners in 2026 Roche initiated the Phase 3 PARAISO trial evaluating prasinezumab in early-stage Parkinson’s disease in 4Q 2025; primary completion expected in 2029 Novo Nordisk initiated the Phase 3 CLEOPATTRA trial evaluating coramitug in ATTR amyloidosis with cardiomyopathy in 4Q 2025; primary completion expected in 2029 Bristol Myers Squibb fully enrolled the Phase 2 TargetTau-1 trial evaluating BMS-986446 in early Alzheimer’s disease with primary completion expected in 1H 2027, completed a Phase 1 trial evaluating a subcutaneous formulation of BMS-986446 and obtained Fast Track designation from the U.S. FDA for BMS-986446 for the treatment of Alzheimer’s disease Prothena presented preclinical data on its TDP-43 CYTOPE® program at Neuroscience 2025 (SfN) and at the International Symposium on ALS/MND demonstrating the potential of Prothena’s CYTOPE® technology to target intracellular disease pathways At the Extraordinary General Meeting on November 19, 2025 Prothena obtained shareholder approval to reduce share capital to create distributable reserves to support a share redemption program to be conducted in 2026 if deemed appropriate Potential to earn up to $105 million in aggregate clinical milestone payments by end of 2026 related to the advancement of both coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb